These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 9003469)

  • 1. Tumor reactivity of immune T cells in short-term culture.
    Krauss JC; Stein JM; Shu S
    Cancer Immunol Immunother; 1996 Dec; 43(4):231-9. PubMed ID: 9003469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes.
    Kagamu H; Shu S
    J Immunol; 1998 Apr; 160(7):3444-52. PubMed ID: 9531305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of subcutaneous tumor with adoptively transferred T cells.
    Peng L; Shu S; Krauss JC
    Cell Immunol; 1997 May; 178(1):24-32. PubMed ID: 9184695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion.
    Wang LX; Chen BG; Plautz GE
    J Immunol; 2002 Sep; 169(6):3314-20. PubMed ID: 12218152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
    J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
    Winter H; Hu HM; McClain K; Urba WJ; Fox BA
    J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases.
    Caldwell SA; Ryan MH; McDuffie E; Abrams SI
    J Immunol; 2003 Sep; 171(5):2402-12. PubMed ID: 12928387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. gamma-Interferon plays a key role in T-cell-induced tumor regression.
    Tuttle TM; McCrady CW; Inge TH; Salour M; Bear HD
    Cancer Res; 1993 Feb; 53(4):833-9. PubMed ID: 8428364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
    Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
    J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-gamma mechanisms that cannot be predicted from in vitro T cell characteristics.
    Peng L; Krauss JC; Plautz GE; Mukai S; Shu S; Cohen PA
    J Immunol; 2000 Dec; 165(12):7116-24. PubMed ID: 11120842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
    Shu S; Krinock RA; Matsumura T; Sussman JJ; Fox BA; Chang AE; Terman DS
    J Immunol; 1994 Feb; 152(3):1277-88. PubMed ID: 8301131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.
    Shu S; Rosenberg SA
    J Immunol; 1985 Oct; 135(4):2895-903. PubMed ID: 2411817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma.
    Sakai K; Chang AE; Shu SY
    Cancer Res; 1990 Jul; 50(14):4371-6. PubMed ID: 2114215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
    Shu SY; Chou T; Rosenberg SA
    J Immunol; 1987 Jul; 139(1):295-304. PubMed ID: 2953816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor antigen-specific immunization of bone marrow transplantation donors as adoptive therapy against established tumor.
    Hornung RL; Longo DL; Bowersox OC; Kwak LW
    J Natl Cancer Inst; 1995 Sep; 87(17):1289-96. PubMed ID: 7544833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. Culture requirements and characterization of immunologic specificity.
    Chou T; Chang AE; Shu SY
    J Immunol; 1988 Apr; 140(7):2453-61. PubMed ID: 2450925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
    J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
    Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
    J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effector phenotype and immunologic specificity of T-cell-mediated adoptive therapy for a murine tumor that lacks intrinsic immunogenicity.
    Sakai K; Chang AE; Shu S
    Cell Immunol; 1990 Aug; 129(1):241-55. PubMed ID: 2364440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive transfer of bryostatin 1-activated T cells provides long-term protection from tumour metastases.
    Tuttle TM; Inge TH; Lind DS; Bear HD
    Surg Oncol; 1992 Aug; 1(4):299-307. PubMed ID: 1341264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.